The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.The Financial Times was the first to report the deal.Pipeline Pressure Mounts Ahead Of Keytruda ExpiryThe deal reflects Merck's broader strategy to replenish its pipeline ahead of Keytruda's expected patent expiry as early as 2028.Keytruda, a cancer immunotherapy, generates about $30 billion annually, making it central to the company's growth trajectory.Merck has been among the most aggressive acquirers in bio ...

Shareholder Alert: The Ademi Firm investigates whether Terns Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders Accessibility StatementSkip NavigationMILWAUKEE, March 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Terns (NASDAQ: TERN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.Click hereto learn how to join our investigation and obtain additional information or contact us at [email protected]or toll-free: 866- ...

Merck & Co (NYSE:MRK) M&A announcement March 25, 2026 08:00 AM ET Company ParticipantsCaroline Litchfield - CFODean Li - President of Merck Research LaboratoriesEvan Seigerman - Managing Director and Head of Healthcare ResearchJannie Oosthuizen - EVP and President of Oncology and MSD InternationalJason Gerberry - Managing Director of Equity ResearchLuisa Hector - Head of Global Pharma Equity Research and Co-Head of the Global Pharmaceuticals TeamMarjorie Green - SVP and Head of Oncology, Global Clinical Dev ...

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a ...

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) to Merck for $53.00 per share in cash. TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pha ...

Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia. ...

Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, the company said Wednesday.This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Terns shares rose 5.3% while Merck stock was largely flat in premarket trading. This is breaking news. Please refresh for updates. ...

默克公司将以约67亿美元的股权价值收购TERNS公司，每股53美元。 ...

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv March 25 (Reuters) - Merck (MRK.N), opens new tabsaid on Wednesday it would buy biotech Terns Pharma (TERN.O), opens new tabin a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda. Sign up here. Reporting by ...

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection. ...